Navigation Links
Northwest Biotherapeutics Secures $700,000 Equity Financing
Date:2/10/2009

BETHESDA, Md., Feb. 10 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC Bulletin Board: NWBO) (the "Company") announces today receipt of $700,000 in cash from Al Rajhi Holdings through the subscription of 1,000,000 new shares in the form of the Company's common stock at $0.70 per share. The new stock is expected to be admitted to trading on AIM on 16 February 2009. The shares will not be tradable on the Company's OTC bulletin board listing in the US without prior registration. The proceeds will be used to support the Company's ongoing working capital needs.

"We are very pleased to have completed another interim financing despite severely adverse general market conditions," said NWBT's Chief Executive Officer Alton Boynton. "We look forward to continuing the financing discussions currently under way with several additional parties for short-term and long-term funding of the Company".

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at http://www.nwbio.com.

Disclaimer


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
2. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Secures US$1.0 Million Debt Financing
5. Northwestern chemists take gold, mass-produce Beijing Olympic logo
6. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
7. Northwestern chemist investigates lost reds in Homer painting
8. Nikon Instruments Opens New Imaging Center at Northwestern University
9. Northwest Secures US$4.0 Million in Debt Financing
10. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
11. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... 14, 2014 During the 1600’s through the ... “The Doctor’s Plague.” In this time period, doctors did not ... at times, to the death of vulnerable patients. In the ... that they may be unwittingly transmitting herpes viruses to their ...
(Date:1/14/2014)... 14, 2014 BioMedomics, Inc. , a ... diagnostic platforms and novel disease specific POC tests, announced today ... netting a total of $690,000. The investment is from private ... company. This group of private investors has significant successful experience ...
Breaking Biology Technology:Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2
... - Two Milestones Reached in Zonisamide Patent Portfolio ... Therapeutics,Inc. (Nasdaq: OREX ), a biopharmaceutical company ... nervous system-related disorders, today,announced the initiation of its ... formulation of zonisamide plus olanzapine.,The Phase 2a clinical ...
... 2 Clarient, Inc.,(Nasdaq: CLRT ), a ... pathologists, oncologists and the pharmaceutical industry,today announced that ... an,exclusive interview on WallSt.net,s 3-Minute Press Show., ... company, and the,significance of the company,s latest press ...
... Zevalin only Radioimmunotherapy in U.S. to be Indicated ... for Use ... Inc. (CTI),(Nasdaq and MTA: CTIC) announced today that it has ... and Drug,Administration (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as,consolidation ...
Cached Biology Technology:Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 2Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 3Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 4[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute Press Show 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5
(Date:4/23/2014)... Valley, NY. (Apr. 23, 2014) People who have ... potential to restore neurological function. However, a study conducted ... issue of Cell Transplantation , but is currently ... http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one group ... cells (PBSCs) injected directly into the brain and a ...
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... term for novels and films which focus on the consequences ... how these fictions serve as a mental laboratory that allows ... imagine other living conditions. , "Global warming is much ... is also a cultural phenomenon in which meaning is being ... see. And there are so many of them now that ...
Breaking Biology News(10 mins):Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... may begin in the womb, researchers from Tel Aviv University ... twin can compromise the health of his twin sister before ... published in the journal Pediatrics, the researchers analyzed the incidence ... twins. When born premature, girls who share the womb with ...
... A recent University of Iowa study reveals a biological link ... women than men are diagnosed with chronic pain and fatigue ... mice, the researchers, led by Kathleen Sluka, Ph.D., professor in ... the UI Roy J. and Lucille A. Carver College of ...
... 2008 The Global Innovation Imperatives (Gii) project ... their first session at the American Chemical Societys ... a joint collaboration between the ACS Committee on ... seeks to combat worldwide health, environmental and societal ...
Cached Biology News:War between the sexes begins before twins' birth, TAU researchers say 2U. Iowa study finds biological link between pain and fatigue 2At ACS' national meeting, global initiative set to tackle water issues 2
... 10 ,Yeast extract, 5 ,Sodium chloride, ... ammonium citrate, 0.5 ,IPTG, 0.03 ... autoclavable chromogenic substrate for -galactosidase. The ... generates a black insoluble precipitate. Lac+ ...
S-100 alpha/beta chain (8B10)...
SCCRO (S-17)...
... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...
Biology Products: